Search - tctmd.com

Displaying 41 - 60 of 104

Sort: Relevancy | Date

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Todd Neale

August 27, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

Podcast TCTMD Talking Points

The EMPEROR-Preserved Trial

August 10, 2022

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

L.A. McKeown

June 21, 2022

News Conference News ESC Heart Failure 2022

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Shelley Wood

May 25, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Conference News HRS 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

Todd Neale

May 02, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2022

Caitlin E. Cox

April 01, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2022

Shelley Wood

February 28, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

L.A. McKeown

February 07, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for November 2021

Shelley Wood

November 30, 2021

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Todd Neale

November 17, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Shelley Wood

November 14, 2021

Advertisement

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

What’s Going to Be Hot at ESC 2022?

The EMPEROR-Preserved Trial

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Dapagliflozin Boosts Health Status Across LVEF Range

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

TCTMD’s Top 10 Most Popular Stories for March 2022

TCTMD’s Top 10 Most Popular Stories for February 2022

FDA Approves Empagliflozin for Treatment of HFpEF

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

TCTMD’s Top 10 Most Popular Stories for November 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Canagliflozin Improves Quality of Life in HF Patients

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content